<?xml version="1.0" encoding="ISO-8859-1"?>
<!DOCTYPE ichicsr SYSTEM "http://www.accessdata.fda.gov/xml/icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053178_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134155</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHHO2005DE11666</safetyreportid>
		<primarysourcecountry>DE</primarysourcecountry>
		<occurcountry>DE</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20121211</transmissiondate>
		<reporttype>2</reporttype>
		<serious>1</serious>
		<seriousnessdeath>1</seriousnessdeath>
		<seriousnesslifethreatening>1</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20050726</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20121206</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2005DE11666</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>DE</reportercountry>
			<qualification>1</qualification>
			<observestudytype>3</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientonsetage>64</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Incisional drainage</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Abdominal hernia repair</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20041011</patientmedicalstartdate>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>102</patientmedicalenddateformat>
				<patientmedicalenddate>20060416</patientmedicalenddate>
			</medicalhistoryepisode>
			<patientdeath>
				<patientdeathdateformat>102</patientdeathdateformat>
				<patientdeathdate>20070216</patientdeathdate>
				<patientautopsyyesno>3</patientautopsyyesno>
				<patientdeathcause>
					<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
					<patientdeathreport>Aortic valve stenosis</patientdeathreport>
				</patientdeathcause>
			</patientdeath>
			<reaction>
				<primarysourcereaction>Relapsing abdominal hernia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Abdominal hernia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal hernia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20041103</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20060416</reactionenddate>
				<reactionduration>530</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>127</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Aortic valve stenosis</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Aortic valve stenosis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Aortic valve stenosis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20070129</reactionstartdate>
				<reactionfirsttime>944</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>5</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Incarcerated hernia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Incarcerated hernia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hernia obstructive</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20060414</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20060509</reactionenddate>
				<reactionduration>26</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>654</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>There was an area of necrotic small intestine which he had excised</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Intestinal necrosis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Gastrointestinal necrosis</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20060414</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20060416</reactionenddate>
				<reactionduration>3</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>654</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Subendocardial myocardial infarction without ST elevation</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Subendocardial myocardial infarction</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Myocardial infarction</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20040701</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20060503</reactionenddate>
				<reactionduration>672</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Hypervolaemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Hypervolaemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Hypervolaemia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20050701</reactionstartdate>
				<reactionfirsttime>367</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Tachycardial arrhythmia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Tachyarrhythmia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Tachyarrhythmia</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20050701</reactionstartdate>
				<reactionfirsttime>367</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Angina</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Angina pectoris</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Angina pectoris</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20050701</reactionstartdate>
				<reactionfirsttime>367</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Adverse event toxicity</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Drug toxicity</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Toxicity to various agents</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20041014</reactionstartdate>
				<reactionfirsttime>107</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Seroma</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Seroma</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Seroma</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Rejection</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Kidney transplant rejection</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Kidney transplant rejection</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>6</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Arrhythmia absoluta</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Arrhythmia absoluta</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Atrial fibrillation</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionoutcome>3</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Non STEMI post surgery</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Non STEMI</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Acute myocardial infarction</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20040715</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20041027</reactionenddate>
				<reactionduration>105</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>16</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<test>
				<testname>Arteriogram coronary</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Investigation</testname>
				<moreinformation>1</moreinformation>
			</test>
			<test>
				<testname>Troponin</testname>
				<testresult>0.68</testresult>
				<testunit>mg/ml</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Troponin</testname>
				<testresult>0.68</testresult>
				<testunit>mg/ml</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>CYCLOSPORIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationnumb>50-715</drugauthorizationnumb>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>170</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>43180</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>170 mg, BID</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20040630</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20041105</drugenddate>
				<drugtreatmentduration>129</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>1</actiondrug>
				<activesubstance>
					<activesubstancename>CICLOSPORIN</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal hernia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal hernia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Acute myocardial infarction</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Acute myocardial infarction</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Angina pectoris</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Angina pectoris</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Aortic valve stenosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Aortic valve stenosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Atrial fibrillation</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Atrial fibrillation</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Gastrointestinal necrosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Gastrointestinal necrosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hernia obstructive</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hernia obstructive</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypervolaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Hypervolaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Kidney transplant rejection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Kidney transplant rejection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Seroma</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Seroma</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Tachyarrhythmia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Tachyarrhythmia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Toxicity to various agents</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Toxicity to various agents</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>MYCOPHENOLATE MOFETIL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit>002</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>1 g, BID</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20040630</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20041012</drugenddate>
				<drugtreatmentduration>105</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MYCOPHENOLATE MOFETIL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>MYCOPHENOLATE MOFETIL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>250</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>250 mg, BID</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20041013</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20050519</drugenddate>
				<drugtreatmentduration>219</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MYCOPHENOLATE MOFETIL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>MYCOPHENOLATE MOFETIL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>1000</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>1000 mg, QD</drugdosagetext>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20060526</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>MYCOPHENOLATE MOFETIL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREDNISOLONE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>250</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>11975</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>500 mg, QD</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20040630</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20040701</drugenddate>
				<drugtreatmentduration>2</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISOLONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREDNISOLONE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>75</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>11975</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>75 mg, QD</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20040701</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20040701</drugenddate>
				<drugtreatmentduration>1</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISOLONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREDNISOLONE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>11975</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>100 mg, QD</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20040702</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20041018</drugenddate>
				<drugtreatmentduration>109</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISOLONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREDNISOLONE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>250</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>11975</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>250 mg, QD</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20041019</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20041020</drugenddate>
				<drugtreatmentduration>2</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISOLONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREDNISOLONE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugcumulativedosagenumb>11975</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>NO TREATMENT</drugdosagetext>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20041021</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20041021</drugenddate>
				<drugtreatmentduration>1</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISOLONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>PREDNISOLONE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>11975</drugcumulativedosagenumb>
				<drugcumulativedosageunit>003</drugcumulativedosageunit>
				<drugdosagetext>100 mg, QD</drugdosagetext>
				<drugadministrationroute>048</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20041022</drugstartdate>
				<drugstartperiod>127</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PREDNISOLONE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>DACLIZUMAB</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit>007</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>813</drugintervaldosagedefinition>
				<drugdosagetext>2 mg/kg, (170mg) ONCE</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20040630</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>20040713</drugenddate>
				<drugtreatmentduration>14</drugtreatmentduration>
				<drugtreatmentdurationunit>804</drugtreatmentdurationunit>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DACLIZUMAB</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>DACLIZUMAB</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugstructuredosagenumb>85</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugdosagetext>85 mg, once per 2 weeks for 4 weeks</drugdosagetext>
				<drugadministrationroute>042</drugadministrationroute>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20040714</drugstartdate>
				<actiondrug>2</actiondrug>
				<drugrecurreadministration>3</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>DACLIZUMAB</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>TACROLIMUS</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<drugdosagetext>UNK, UNK</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Renal transplant</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>20041104</drugstartdate>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>TACROLIMUS</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>PANTOZOL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>PANTOPRAZOLE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>BELOC ZOK</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>METOPROLOL SUCCINATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>EUTHYROX</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>SPASMEX</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>TROSPIUM CHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>UNACID</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>AMPICILLIN SODIUM, SULBACTAM SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>KEPINOL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>SULFAMETHOXAZOLE, TRIMETHOPRIM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ACETYLCYSTEINE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>ACETYLCYSTEINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ASPIRIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>ACETYLSALICYLIC ACID</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CIPROFLOXACIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>CIPROFLOXACIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>DIGITOXIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>DIGITOXIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>FUROSEMID</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>FUROSEMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>FLUVASTATIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>FLUVASTATIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>KALIUM-DURILES</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>POTASSIUM CHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>RISEDRONATE SODIUM</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>RISEDRONATE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>TEMAZEPAM</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>TEMAZEPAM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ISONIAZID</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>ISONIAZID</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>ENOXAPARIN SODIUM</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>ENOXAPARIN SODIUM, HEPARIN-FRACTION, SODIUM SALT</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>CLOPIDOGREL</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>CLOPIDOGREL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>COLCHICUM AUTUMNALE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>COLCHICUM AUTUMNALE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>TORASEMIDE</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>TORASEMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization>2</drugcharacterization>
				<medicinalproduct>SULTAMICILLIN</medicinalproduct>
				<obtaindrugcountry>DE</obtaindrugcountry>
				<drugauthorizationcountry>DE</drugauthorizationcountry>
				<actiondrug>5</actiondrug>
				<activesubstance>
					<activesubstancename>SULTAMICILLIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Initial report received on 26 Jul 2005: Report from a Non-Novartis trial.  Patient number 161045 was enrolled in the Elite-Symphony study, evaluating the safety and efficacy of mycophenolate mofetil, daclizumab and corticosteroids as mainstay immunosuppression in combination with low-dose cyclosporine, tacrolimus or sirolimus in comparison to current standard immunosuppression (mycophenolate mofetil, cyclosporine and corticosteroids) in renal transplantation.  The patient was concomitantly taking digitoxin, furosemide and potassium chloride.  A 65 year old male patient experienced a life-threatening subendocardial myocardial infection (reported term: non STEMI), arrhythmia absoluta and a relapsing abdominal hernia during participation in the above study.  He underwent renal transplantation on 30 June 2004 and received one 2 mg/kg dose of intravenous (IV) daclizumab, as per protocol and 250 mg IV prednisolone.  Oral mycophenolate mofetil and ciclosporin (Novartis product) were commenced at 1 gram and 170 mg twice daily respectively.  On post-operative day 1, he received a second dose of IV prednisolone and oral prednisolone was commenced at 75 mg once daily.  He developed hypervolaemia, "tachycardial arrhythmia and angina" with a "positive troponin" result (0.68 mg/mL).  Conservative treatment was commenced with anti-angina drugs and he underwent diagnostic angiography of the coronary arteries.  Due to minimal troponin elevation, the diagnosis was a life-threatening myocardial infarction without ST elevation, which required intervention. This event was considered to have resolved on post-operative day 22.  On an unspecified date, the patient developed an abdominal hernia and a planned correction was performed on 11 October 2004.  Three days later, mycophenolate mofetil was decreased to 250 mg twice daily "due to adverse event toxicity".  Approximately two weeks later, on 03 November 2004 he was admitted to hospital with a relapsing abdominal hernia, which was now considered to be serious. He also developed a seroma, for which punctuation was done. Two days later, ciclosporin was switched to tacrolimus.  The investigator stated that a second hernia correction was not performed during this hospitalisation due to ongoing high dose steroids following rejection and also because of the change in medication from ciclosporin to tacrolimus.  Six days later, he was discharged from hospital.  On 14 November 2004 he was hospitalised for a planned correction of the hernia.  However, 'cardial diagnostics had to be done before the operation and the following day he was reported to have arrhythmia absoluta.  As a result of the arrhythmia absoluta, the second hernia correction was not performed.  He received treatment with enoxaparin sodium (Clexane), potassium bicarbonate (Kalitrans), magnesium (magnesium verla) and the dose of metoprolol succinate (Belok-Zok), which he was already taking (non-suspect drug) was increased.  The dosages of oral prednisolone and cyclosporine had been altered several times, and were ongoing and he had received several further 250 mg doses of IV prednisolone due to rejection episodes.  No further information was available.  At the time of the report, the relapsing abdominal hernia and the "arrhythmia absoluta" were persisting and treatment with mycophenolate mofetil, prednisolone and tacrolimus were ongoing.  The investigator considered the myocardial infarction and relapsing abdominal hernia to be medically significant.  The investigator considered the myocardial infarction to be unrelated to daclizumab, mycophenolate mofetil, ciclosporin and prednisolone, but the relapsing abdominal hernia was considered related to mycophenolate mofetil, ciclosporin and prednisolone and unrelated to daclizumab.  The investigator considered arrhythmia absoluta to be unrelated to daclizumab, mycophenolate mofetil, ciclosporin, tacrolimus and prednisolone and did not provide a causality assessment between arrhythmia absoluta and prednisolone.

Follow-up received on 17 May 2006:  On 14 Apr 2006, the patient developed an incarcerated hernia, for which he was readmitted to hospital.  There was an area of necrotic small intestine which he had excised, following which this event improved.  The investigator assessed this event to be life threatening.  The investigator considered the incarcerated hernia due to the abdominal hernia.

Follow-up received on 15 May 2007:  The dose of mycophenolate mofetil was adjusted to 2000 mg daily, prednisolone to 5 mg daily, and tacrolimus to 4 mg daily.  On an unknown date, the patient experienced aortic valve stenosis.  This became serious on 29 Jan 2007 and the patient was hospitalised.  Eighteen days later he died due to the event of aortic stenosis.  The relapsing abdominal hernia and the arrhythmia absoluta were persisting and treatment with Mycophenolate Mofetil (MMF), Prednisolone and Tacrolimus were ongoing.  The investigator considered the aortic valve stenosis (fatal) to be unrelated to all study medications and stated that a possible alternative cause for the event was a pre-existing underlying disease causing cardiac respiratory-cardiac arrest.  The investigator considered the myocardial infarction and incarcerated hernia to be life-threatening and the relapsing abdominal hernia to be medically significant.  The myocardial infarction was considered unrelated to MMF, ciclosporin, prednisolone and daclizumab.  The relapsing abdominal hernia was considered related to MMF, ciclosporin and prednisolone, and unrelated to daclizumab.  The arrhythmia absoluta was unrelated to daclizumab, MMF, ciclosporin and tacrolimus.  The incarcerated hernia was due to the abdominal hernia and was unrelated to the study medication.

Follow up received 19 Jun 2009 from Roche, MCN 372972: On 30 Jun 2004, the patient commenced IV daclizumab 170mg once, mycophenolate mofetil 2g daily, cyclosporine 340mg and prednisolone 500mg once. On postoperative day 1, intravenous prednisolone was changed to oral at 75mg, once. The same day, oral prednisolone was again changed to intravenous 250mg once. The following day, the patient received oral prednisolone at 100mg daily. On 14 Jul 2004, the dose of daclizumab was reduced to 85mg once per 2 weeks for four weeks. On 23 Jul 2004, the patient experienced non-STEMI post surgery (non ST elevation myocardial infarction). On 13 Oct 2004, the dose of mycophenolate mofetil was reduced to 500mg daily due to 'adverse event toxicity'. On 19 Oct 2004, oral prednisolone was changed to intravenous at 250mg daily. The next day, oral prednisolone was discontinued. On 22 Oct 2004, oral prednisolone was restarted at 100mg daily. On 27 Oct 2004, the event of non-STEMI post surgery resolved. Cyclosporin was discontinued on 05 Nov 2004.  On 16 Apr 2006, the event of relapsing abdominal hernia resolved. The next day, the patient experienced myocardial infarct and was hospitalized. On 03 May 2006, the event of myocardial infarct resolved. On 20 May 2006, mycophenolate mofetil was increased to 1000mg daily. On 29 Jan 2007, the patient experienced aortic valve stenosis which became serious and he was hospitalized. On 16 Feb 2007, the patient died due to aortic valve stenosis. The investigator assessed all the events as unrelated to the use of daclizumab. The event of relapsing abdominal hernia was related and all other events were unrelated to the use of mycophenolate mofetil, cyclosporin (Novartis drug) and corticosteroids.

Follow up received on 06 Dec 2012: The investigator confirmed that, the subject was diagnosed with relapsing abdominal hernia on 03 Nov 2004 and on 09 May 2006, the subject recovered from incarcerated hernia.</narrativeincludeclinical>
				<sendercomment>MAC: The events hernia obstructive and abdominal hernia can be possible explained as surgical complications, but the lack of relevant details excludes a meaningful medical assessment. A causal relationship to drug cannot be rule out.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
